Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2024-03-18 13:11 Tx date 2024-03-13 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$100,000
+100,000 vol $1.00 each |
1,387,500 | |
Filed 2024-03-18 13:11 Tx date 2024-03-13 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$100,000
+100,000 vol $1.00 each |
576,000 | |
Filed 2024-03-12 14:15 Tx date 2024-03-12 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$100,000
+100,000 vol $1.00 each |
400,000 | |
Filed 2024-03-12 14:14 Tx date 2024-03-12 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-100,000
-100,000 vol $1.00 each |
225,000 | |
Filed 2024-03-12 14:11 Tx date 2024-03-11 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-450,000
-150,000 vol $3.00 each |
300,000 | |
Filed 2024-02-27 01:05 Tx date 2024-02-22 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$100,000
+100,000 vol $1.00 each |
1,100,000 | |
Filed 2024-02-27 00:29 Tx date 2024-02-22 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-100,000
-100,000 vol $1.00 each |
225,000 | |
Filed 2024-02-21 00:12 Tx date 2024-02-19 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$278,400
+80,000 vol $3.48 each |
1,180,000 | |
Filed 2024-02-21 00:06 Tx date 2024-02-19 |
$NGEN
NervGen Pharma Corp. |
Mikol, Daniel
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$278,400
+80,000 vol $3.48 each |
1,010,000 | |
Filed 2024-02-21 00:03 Tx date 2024-02-19 |
$NGEN
NervGen Pharma Corp. |
Kelly, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,201,296
+345,200 vol $3.48 each |
3,207,200 | |
Filed 2024-01-15 15:18 Tx date 2024-01-08 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,977
+2,000 vol $1.99 each |
2,000 | |
Filed 2024-01-08 13:59 Tx date 2024-01-08 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,977
+2,000 vol $1.99 each |
||
Filed 2024-01-08 13:59 Tx date 2024-01-08 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,977
+2,000 vol $1.99 each |
2,000 | |
Filed 2024-01-08 13:56 Tx date 2021-09-09 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2023-11-27 12:01 Tx date 2023-11-27 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$-1,920
-1,000 vol $1.92 each |
1,287,500 | |
Filed 2023-10-20 17:42 Tx date 2023-10-16 |
$NGEN
NervGen Pharma Corp. |
Ruffolo, John
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$262,500
+150,000 vol $1.75 each |
150,000 | |
Filed 2023-10-20 17:39 Tx date 2023-10-16 |
$NGEN
NervGen Pharma Corp. |
Ruffolo, John
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2023-10-20 17:37 Tx date 2023-10-16 |
$NGEN
NervGen Pharma Corp. |
Ruffolo, John
4 - Director of Issuer
Holder: Carryn Ruffolo (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
27,027 | ||
Filed 2023-10-02 17:36 Tx date 2023-09-27 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,000
-1,000 vol $2.00 each |
1,288,500 | |
Filed 2023-05-25 12:21 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
325,000 | |
Filed 2023-05-25 11:32 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Thompson, John Craig
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
275,000 | |
Filed 2023-05-25 11:16 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
300,000 | |
Filed 2023-05-24 12:03 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
325,000 | |
Filed 2023-05-24 11:53 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
225,000 | |
Filed 2023-05-24 11:12 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
375,000 | |
Filed 2023-05-24 00:26 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
476,000 | |
Filed 2023-05-23 21:19 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
300,000 | |
Filed 2023-04-17 17:11 Tx date 2023-04-10 |
$NGEN
NervGen Pharma Corp. |
Kelly, Michael
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$5,094,360
+2,862,000 vol $1.78 each |
2,862,000 | |
Filed 2023-04-17 17:08 Tx date 2023-04-10 |
$NGEN
NervGen Pharma Corp. |
Kelly, Michael
4 - Director of Issuer
Direct Ownership
|
Retention Securities
97 - Other
|
$1,050,200
+590,000 vol $1.78 each |
590,000 | |
Filed 2023-04-17 17:00 Tx date 2023-04-10 |
$NGEN
NervGen Pharma Corp. |
Kelly, Michael
4 - Director of Issuer
Direct Ownership
|
Retention Securities
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2023-04-17 14:39 Tx date 2023-04-10 |
$NGEN
NervGen Pharma Corp. |
Kelly, Michael
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2023-02-28 20:51 Tx date 2023-02-28 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Common Shares
47 - Acquisition or disposition by gift
|
-1,450,000 vol |
1,000,000 | |
Filed 2023-02-28 10:49 Tx date 2023-02-28 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$116,400
+60,000 vol $1.94 each |
426,000 | |
Filed 2023-02-24 21:42 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$48,500
+25,000 vol $1.94 each |
175,000 | |
Filed 2023-02-24 21:15 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$48,500
+25,000 vol $1.94 each |
325,000 | |
Filed 2023-02-24 20:50 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
$97,000
+50,000 vol $1.94 each |
250,000 | |
Filed 2023-02-24 17:56 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Mikol, Daniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$155,200
+80,000 vol $1.94 each |
930,000 | |
Filed 2023-02-24 17:26 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Thompson, John Craig
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$48,500
+25,000 vol $1.94 each |
225,000 | |
Filed 2023-02-24 16:19 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$155,200
+80,000 vol $1.94 each |
1,100,000 | |
Filed 2023-02-24 14:32 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$48,500
+25,000 vol $1.94 each |
275,000 | |
Filed 2023-02-24 14:27 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$97,000
+50,000 vol $1.94 each |
250,000 | |
Filed 2023-02-24 13:44 Tx date 2023-02-23 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
275,000 | |
Filed 2023-01-16 16:32 Tx date 2023-01-10 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-312,000
-150,000 vol $2.08 each |
366,000 | |
Filed 2022-11-28 22:34 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
200,000 | |
Filed 2022-11-18 11:20 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
250,000 | |
Filed 2022-11-18 10:27 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
516,000 | |
Filed 2022-11-17 17:14 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Thompson, John Craig
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
200,000 | |
Filed 2022-11-17 17:04 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
150,000 | |
Filed 2022-11-17 17:03 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
300,000 | |
Filed 2022-11-17 16:58 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
250,000 | |
Filed 2022-11-17 16:54 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
200,000 | |
Filed 2022-08-24 15:12 Tx date 2022-08-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,275
-5,500 vol $2.05 each |
1,289,500 | |
Filed 2022-07-20 13:28 Tx date 2022-07-13 |
$NGEN
NervGen Pharma Corp. |
PFP Biosciences Holdings LLC
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
5,000,000 | ||
Filed 2022-07-20 13:27 Tx date 2022-07-13 |
$NGEN
NervGen Pharma Corp. |
PFP Biosciences Holdings LLC
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
10,000,000 | ||
Filed 2022-07-20 13:02 Tx date 2022-07-15 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
150,000 | |
Filed 2022-07-20 13:01 Tx date 2022-07-13 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-07-20 13:00 Tx date 2022-07-13 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
10,000 | ||
Filed 2022-07-20 12:57 Tx date 2022-07-13 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: PFP Biosciences Holdings LLC (Control or Direction)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
5,000,000 | ||
Filed 2022-07-20 12:54 Tx date 2022-07-13 |
$NGEN
NervGen Pharma Corp. |
Rogers, Adam
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: PFP Biosciences Holdings LLC (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
10,000,000 | ||
Filed 2022-06-01 12:24 Tx date 2022-05-31 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$374,400
+180,000 vol $2.08 each |
466,000 | |
Filed 2022-06-01 12:19 Tx date 2022-05-31 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-221,000
-100,000 vol $2.21 each |
286,000 | |
Filed 2022-05-05 19:38 Tx date 2022-05-04 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$80,000
+50,000 vol $1.60 each |
619,354 | |
Filed 2022-05-05 19:36 Tx date 2022-05-04 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
-50,000 vol |
9,676 | |
Filed 2022-04-27 20:31 Tx date 2022-04-27 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Common Shares
54 - Exercise of warrants
|
$76,800
+48,000 vol $1.60 each |
111,750 | |
Filed 2022-04-27 20:24 Tx date 2022-04-27 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Warrants
54 - Exercise of warrants
|
-48,000 vol |
7,875 | |
Filed 2022-04-27 20:02 Tx date 2022-04-26 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$160,000
+100,000 vol $1.60 each |
2,450,000 | |
Filed 2022-04-27 19:51 Tx date 2022-04-26 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-160,000
-100,000 vol $1.60 each |
0 | |
Filed 2022-04-27 19:47 Tx date 2022-04-26 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$160,000
+100,000 vol $1.60 each |
||
Filed 2022-04-27 19:45 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+100,000 vol |
100,000 | |
Filed 2022-04-27 19:43 Tx date 2017-01-19 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-04-26 15:33 Tx date 2022-04-26 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$160,000
+100,000 vol $1.60 each |
450,000 | |
Filed 2022-04-26 15:30 Tx date 2022-04-26 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-160,000
-100,000 vol $1.60 each |
0 | |
Filed 2022-04-18 15:45 Tx date 2022-04-12 |
$NGEN
NervGen Pharma Corp. |
Thompson, John Craig
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$330,000
+150,000 vol $2.20 each |
150,000 | |
Filed 2022-04-18 15:43 Tx date 2022-04-12 |
$NGEN
NervGen Pharma Corp. |
Thompson, John Craig
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-04-18 12:48 Tx date 2022-04-12 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$110,000
+50,000 vol $2.20 each |
250,000 | |
Filed 2022-04-18 12:44 Tx date 2022-04-12 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$110,000
+50,000 vol $2.20 each |
100,000 | |
Filed 2022-04-18 12:42 Tx date 2022-04-12 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$110,000
+50,000 vol $2.20 each |
150,000 | |
Filed 2022-03-16 13:26 Tx date 2021-01-04 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$111,500
+50,000 vol $2.23 each |
150,000 | |
Filed 2022-03-07 20:53 Tx date 2022-03-01 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$247,200
+120,000 vol $2.06 each |
1,110,000 | |
Filed 2022-03-07 17:16 Tx date 2022-03-01 |
$NGEN
NervGen Pharma Corp. |
Mikol, Daniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$103,000
+50,000 vol $2.06 each |
850,000 | |
Filed 2022-03-07 16:44 Tx date 2022-03-01 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$164,800
+80,000 vol $2.06 each |
1,020,000 | |
Filed 2021-11-29 13:16 Tx date 2021-11-29 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+80,000 vol |
80,000 | |
Filed 2021-11-29 13:15 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-11-29 13:12 Tx date 2021-11-29 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$208,000
+80,000 vol $2.60 each |
1,295,000 | |
Filed 2021-09-16 16:09 Tx date 2021-09-13 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$105,000
+50,000 vol $2.10 each |
50,000 | |
Filed 2021-09-16 16:08 Tx date 2021-09-09 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-09-16 16:07 Tx date 2021-09-09 |
$NGEN
NervGen Pharma Corp. |
McKerracher, Krista
4 - Director of Issuer
Holder: Fig Advisory LLC (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
Filed 2021-09-14 22:46 Tx date 2021-09-13 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$105,000
+50,000 vol $2.10 each |
300,000 | |
Filed 2021-09-14 20:08 Tx date 2021-09-13 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$105,000
+50,000 vol $2.10 each |
150,000 | |
Filed 2021-09-14 20:06 Tx date 2021-09-13 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$420,000
+200,000 vol $2.10 each |
386,000 | |
Filed 2021-09-14 20:01 Tx date 2021-09-13 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$210,000
+100,000 vol $2.10 each |
100,000 | |
Filed 2021-09-14 18:15 Tx date 2021-09-13 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$105,000
+50,000 vol $2.10 each |
200,000 | |
Filed 2021-09-13 21:22 Tx date 2021-09-12 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$105,000
+50,000 vol $2.10 each |
||
Filed 2021-09-13 17:50 Tx date 2021-09-12 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$210,000
+100,000 vol $2.10 each |
||
Filed 2021-09-13 21:22 Tx date 2021-09-12 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$105,000
+50,000 vol $2.10 each |
200,000 | |
Filed 2021-09-13 17:50 Tx date 2021-09-12 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$210,000
+100,000 vol $2.10 each |
100,000 | |
Filed 2021-09-13 17:37 Tx date 2021-09-09 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Holder: Glenn Antony Ives Professional Corporatio (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
50,000 | ||
Filed 2021-09-13 17:27 Tx date 2021-09-09 |
$NGEN
NervGen Pharma Corp. |
Ives, Glenn Antony
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-09-13 17:11 Tx date 2021-09-12 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
200,000 | |
Filed 2021-08-28 13:30 Tx date 2021-08-24 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-218,750
-125,000 vol $1.75 each |
1,215,000 | |
Filed 2021-05-14 19:10 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$80,000
+50,000 vol $1.60 each |
50,000 | |
Filed 2021-05-14 19:05 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Common Shares
53 - Grant of warrants
|
$80,000
+50,000 vol $1.60 each |
||
Filed 2021-05-14 18:43 Tx date 2021-05-12 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$20,319
+9,676 vol $2.10 each |
9,676 | |
Filed 2021-05-14 18:39 Tx date 2019-11-26 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-05-14 18:25 Tx date 2021-05-12 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$29,998
+19,354 vol $1.55 each |
619,354 | |
Filed 2021-05-14 13:55 Tx date 2021-05-12 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$16,537
+7,875 vol $2.10 each |
55,875 | |
Filed 2021-05-14 13:52 Tx date 2021-05-12 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$24,412
+15,750 vol $1.55 each |
63,750 | |
Filed 2021-05-14 13:39 Tx date 2021-05-12 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$16,537
+7,875 vol $2.10 each |
||
Filed 2021-05-14 13:37 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-05-14 13:37 Tx date 2021-05-12 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$24,412
+15,750 vol $1.55 each |
||
Filed 2021-05-14 13:35 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-05-21 14:30 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Common Shares
53 - Grant of warrants
|
$80,000
+50,000 vol $1.60 each |
||
Filed 2021-05-10 14:22 Tx date 2021-05-05 |
$NGEN
NervGen Pharma Corp. |
Mikol, Daniel
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
800,000 | ||
Filed 2021-05-06 20:08 Tx date 2021-04-23 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$198,000
+120,000 vol $1.65 each |
990,000 | |
Filed 2021-05-06 19:34 Tx date 2021-04-23 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$132,000
+80,000 vol $1.65 each |
940,000 | |
Filed 2020-11-02 11:41 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$176,000
+100,000 vol $1.76 each |
100,000 | |
Filed 2020-11-02 11:38 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-10-29 18:09 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-10-29 18:09 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
Filed 2020-10-05 23:19 Tx date 2020-09-30 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-585,000
-450,000 vol $1.30 each |
1,340,000 | |
Filed 2020-08-20 22:45 Tx date 2020-05-22 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$175,000
+100,000 vol $1.75 each |
2,350,000 | |
Filed 2020-06-05 12:24 Tx date 2020-06-03 |
$NGEN
NervGen Pharma Corp. |
Punnett, Harold
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$135,000
+50,000 vol $2.70 each |
150,000 | |
Filed 2020-06-04 21:07 Tx date 2020-06-03 |
$NGEN
NervGen Pharma Corp. |
Franke, Amy
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$54,000
+20,000 vol $2.70 each |
272,000 | |
Filed 2020-06-04 20:16 Tx date 2020-06-03 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$135,000
+50,000 vol $2.70 each |
186,000 | |
Filed 2020-06-04 20:05 Tx date 2018-09-05 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$50,000
+100,000 vol $0.50 each |
200,000 | |
Filed 2020-06-04 20:03 Tx date 2020-06-03 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$135,000
+50,000 vol $2.70 each |
250,000 | |
Filed 2020-06-04 11:25 Tx date 2020-06-03 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
150,000 | |
Filed 2020-05-22 17:40 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+100,000 vol |
100,000 | |
Filed 2020-05-22 17:38 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-05-22 17:37 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Bayley, Brian Eric
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$125,000
+100,000 vol $1.25 each |
350,000 | |
Filed 2020-05-21 14:51 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-05-21 14:50 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Units
16 - Acquisition or disposition under a prospectus exemption
|
$60,000
+48,000 vol $1.25 each |
||
Filed 2020-05-21 14:49 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$60,000
+48,000 vol $1.25 each |
48,000 | |
Filed 2020-05-21 14:48 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-05-21 14:46 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$60,000
+48,000 vol $1.25 each |
48,000 | |
Filed 2020-05-21 14:45 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Holder: RBCDS in Trust for William Adams (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-05-21 14:31 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Units
16 - Acquisition or disposition under a prospectus exemption
|
$60,000
+48,000 vol $1.25 each |
||
Filed 2020-05-21 14:30 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Common Shares
53 - Grant of warrants
|
$80,000
+50,000 vol $1.60 each |
600,000 | |
Filed 2020-05-21 14:29 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-05-21 14:28 Tx date 2020-05-20 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$62,500
+50,000 vol $1.25 each |
550,000 | |
Filed 2020-05-21 14:28 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-04-15 11:42 Tx date 2020-04-06 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$79,099
+70,000 vol $1.13 each |
870,000 | |
Filed 2020-04-15 11:07 Tx date 2020-04-06 |
$NGEN
NervGen Pharma Corp. |
Franke, Amy
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$58,759
+52,000 vol $1.13 each |
252,000 | |
Filed 2020-04-15 11:01 Tx date 2020-04-06 |
$NGEN
NervGen Pharma Corp. |
Mackenzie, Lloyd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$70,060
+62,000 vol $1.13 each |
512,000 | |
Filed 2020-04-15 01:56 Tx date 2020-04-06 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$40,679
+36,000 vol $1.13 each |
136,000 | |
Filed 2020-04-14 19:57 Tx date 2020-04-06 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$67,800
+60,000 vol $1.13 each |
860,000 | |
Filed 2020-02-26 09:34 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+800,000 vol |
800,000 | |
Filed 2020-02-26 09:32 Tx date 2020-02-21 |
$NGEN
NervGen Pharma Corp. |
Adams, William James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-01-17 18:56 Tx date 2020-01-13 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-45,900
-15,000 vol $3.06 each |
292,500 | |
Filed 2020-01-11 23:11 Tx date 2020-01-07 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,700
-15,000 vol $2.18 each |
307,500 | |
Filed 2019-12-27 19:18 Tx date 2019-12-23 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-26,400
-15,000 vol $1.76 each |
322,500 | |
Filed 2019-11-29 11:34 Tx date 2019-11-26 |
$NGEN
NervGen Pharma Corp. |
Mackenzie, Lloyd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
450,000 | ||
Filed 2019-11-29 11:32 Tx date 2019-11-26 |
$NGEN
NervGen Pharma Corp. |
Mackenzie, Lloyd
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
250,000 | ||
Filed 2019-11-28 16:16 Tx date 2019-11-26 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
800,000 | ||
Filed 2019-11-28 16:14 Tx date 2019-11-26 |
$NGEN
NervGen Pharma Corp. |
Brennan, Paul Anthony
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
500,000 | ||
Filed 2019-11-06 20:51 Tx date 2019-11-04 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-7,260
-4,400 vol $1.65 each |
337,500 | |
Filed 2019-11-02 14:13 Tx date 2019-11-01 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-24,000
-15,000 vol $1.60 each |
341,900 | |
Filed 2019-11-02 14:12 Tx date 2019-10-31 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,100
-15,000 vol $1.54 each |
356,900 | |
Filed 2019-06-15 11:13 Tx date 2019-06-11 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,526
-3,100 vol $1.46 each |
371,900 | |
Filed 2019-06-03 13:50 Tx date 2019-06-01 |
$NGEN
NervGen Pharma Corp. |
Bosc, Denis
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
Filed 2019-06-03 11:53 Tx date 2019-06-01 |
$NGEN
NervGen Pharma Corp. |
Franke, Amy
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$154,000
+100,000 vol $1.54 each |
200,000 | |
Filed 2019-05-06 12:36 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
Filed 2019-05-06 12:35 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,500,000 | ||
Filed 2019-05-06 12:34 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-05-06 12:34 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-05-06 12:34 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-05-06 12:33 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-05-06 12:32 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-05-06 12:32 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-28 11:26 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-04-28 11:19 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-03-15 16:05 Tx date 2018-06-06 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-03-15 16:03 Tx date 2018-06-06 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-28 11:26 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
100,000 | |
Filed 2019-04-28 11:23 Tx date 2019-01-17 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-04-28 11:21 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
97 - Other
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-04-28 11:19 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
1,500,000 | |
Filed 2019-04-28 11:18 Tx date 2018-06-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-04-28 11:18 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-04-28 11:16 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-04-28 11:10 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
97 - Other
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-04-28 11:02 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-03-15 16:07 Tx date 2019-01-17 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-03-15 16:04 Tx date 2018-06-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-04-27 15:41 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
Filed 2019-04-27 15:39 Tx date 2018-08-21 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-27 15:38 Tx date 2018-09-05 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$50,000
+100,000 vol $0.50 each |
||
Filed 2019-04-27 15:34 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
Filed 2019-04-27 15:31 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
375,000 | ||
Filed 2019-04-27 15:21 Tx date 2018-06-11 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-27 15:21 Tx date 2018-09-05 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
+50,000 vol |
||
Filed 2019-04-27 15:21 Tx date 2018-06-11 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-03-01 13:06 Tx date 2018-09-05 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$50,000
+100,000 vol $0.50 each |
||
Filed 2019-03-01 13:03 Tx date 2018-08-21 |
$NGEN
NervGen Pharma Corp. |
Abrams, Michael Jeffrey
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-02-26 18:24 Tx date 2018-06-11 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-02-26 18:21 Tx date 2018-09-05 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
+50,000 vol |
||
Filed 2019-02-26 18:18 Tx date 2018-06-11 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-02-26 18:14 Tx date 2018-06-11 |
$NGEN
NervGen Pharma Corp. |
Pilz, Robert
5 - Senior Officer of Issuer
Holder: Revelation Business Solutions Ltd. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-26 22:01 Tx date 2019-04-18 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,500
-10,000 vol $1.65 each |
1,790,000 | |
Filed 2019-04-26 22:00 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
Filed 2019-04-26 21:58 Tx date 2019-02-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,800,000 | ||
Filed 2019-04-26 21:54 Tx date 2017-01-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-26 21:54 Tx date 2017-01-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-26 21:53 Tx date 2017-01-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-26 21:53 Tx date 2019-04-16 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,500
-10,000 vol $1.65 each |
||
Filed 2019-04-26 21:51 Tx date 2018-06-25 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$60,000
+300,000 vol $0.20 each |
||
Filed 2019-04-26 21:51 Tx date 2018-06-11 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-04-26 21:49 Tx date 2019-03-01 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-04-18 22:38 Tx date 2019-04-16 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,500
-10,000 vol $1.65 each |
||
Filed 2019-03-04 17:38 Tx date 2019-03-01 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
||
Filed 2019-03-03 16:21 Tx date 2018-06-11 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
||
Filed 2019-03-03 16:20 Tx date 2017-01-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-03-03 16:13 Tx date 2017-01-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-03-03 16:11 Tx date 2018-06-25 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$60,000
+300,000 vol $0.20 each |
||
Filed 2019-03-03 16:10 Tx date 2017-01-19 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-04-18 22:38 Tx date 2019-04-16 |
$NGEN
NervGen Pharma Corp. |
Radvak, William Joseph
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,500
-10,000 vol $1.65 each |
1,790,000 | |
Filed 2019-04-09 13:21 Tx date 2019-04-01 |
$NGEN
NervGen Pharma Corp. |
Franke, Amy
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
Filed 2019-03-15 Tx date 2018-06-06 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-03-15 Tx date 2019-01-17 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+100,000 vol $1.00 each |
100,000 | |
Filed 2019-03-15 Tx date 2018-06-06 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-03-15 Tx date 2018-06-19 |
$NGEN
NervGen Pharma Corp. |
Wong, Ernest Shing-Yan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+1,500,000 vol $0.01 each |
1,500,000 |